TRUSTED BY HEALTHCARE PROFESSIONALS TO
Deliver Short-Acting Relief to Patients
A proven history of COPD treatment and comprehensive support
Healthcare professionals and pulmonologists have been prescribing the rapid relief* of COMBIVENT RESPIMAT for over 12 years. Let’s look at the history and support patients have experienced over those years.
*The median time to onset of bronchodilation for COMBIVENT RESPIMAT is at 13 minutes. COMBIVENT RESPIMAT is not a rescue medication.
Decades of COPD relief
COMBIVENT has been helping patients breathe better for over 25 years.
COMBIVENT RESPIMAT has been delivering its treatment through a soft mist since 2011.
Learn about the RESPIMAT inhaler
More than 7 million prescriptions have been filled since 2018.
Support for your patients and office
Eligible patients pay as little as $35† for a 30-day prescription fill.
Patient resources include educational information, treatment tips, and more.
BI Solutions Plus provides support, resources, and more.
Prior authorization assistance streamlines prescriptions.
†Terms and Conditions Apply.
COMBIVENT RESPIMAT continues to play a vital role in the treatment of COPD, with more than 1.2 million prescriptions filled in 2022.
Short-acting power
COMBIVENT RESPIMAT is the only inhaler for COPD that delivers 2 short-acting bronchodilators that act by 2 different mechanisms.1
Ipratropium Bromide
Cholinergic Receptors
Ipratropium, the anticholinergic component, is believed to induce bronchodilation by inhibiting the bronchoconstrictive effect of acetylcholine on airway smooth muscle.1
Albuterol Sulfate
Beta-Adrenergic Receptors
Albuterol, the beta-2 adrenergic receptor component, is believed to produce bronchodilation by increasing intracellular cyclic AMP‡ that relaxes airway smooth muscle.1
‡AMP=adenosine monophosphate.
See the Power of 2 at work
Watch the video to learn how ipratropium bromide and albuterol sulfate combine in COMBIVENT RESPIMAT.
00:00:02By the time COPD is diagnosed, lung function can be reduced by more than 60%. Although no bronchodilator therapy has been shown to reduce the rate of decline in lung function in patients with COPD, bronchodilators can improve lung function to help partially compensate for lost lung function.COMBIVENT RESPIMAT is the only inhaler for COPD that provides two short-acting bronchodilators that act by two mechanisms.Ipratropium, the anticholinergic component, is believed to induce bronchodilation by inhibiting the bronchoconstrictive effect of acetylcholine on the airway smooth muscle.Albuterol, the beta-2 adrenergic receptor component, is believed to produce bronchodilation by increasing intracellular cyclic AMP that relaxes airway smooth muscle.
00:01:03COMBIVENT RESPIMAT is indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.COMBIVENT RESPIMAT is contraindicated in patients hypersensitive to any of the ingredients of the drug product or to atropine or its derivatives.COMBIVENT RESPIMAT can produce paradoxical bronchospasm that can be life-threatening. If it occurs, therapy with COMBIVENT RESPIMAT should be discontinued immediately and alternative therapy instituted.The albuterol sulfate contained in COMBIVENT RESPIMAT can produce a clinically significant cardiovascular effect in some patients. If cardiovascular symptoms occur, COMBIVENT RESPIMAT may need to be discontinued.COMBIVENT RESPIMAT should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.COMBIVENT RESPIMAT contains ipratropium bromide and may increase intraocular pressure which may result in precipitation or worsening of narrow-angle glaucoma.Patients should avoid spraying the aerosol into their eyes as this may cause acute eye pain or discomfort, temporary blurring of vision, mydriasis, visual halos, or colored images in association with red eyes from conjunctival or corneal congestion. Advise patients to consult their physician immediately if any of these symptoms develop while using COMBIVENT RESPIMAT.Ipratropium bromide may also cause urinary retention.COMBIVENT RESPIMAT should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction.
00:02:50Since dizziness and blurred vision may occur with the use of COMBIVENT RESPIMAT, caution patients about engaging in activities such as driving a vehicle or operating appliances or machinery.Do not exceed recommended dose. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma.Hypersensitivity reactions including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema may occur. If such a reaction occurs, therapy with COMBIVENT RESPIMAT should be stopped at once and alternative treatment should be considered.COMBIVENT RESPIMAT contains albuterol and should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus, and in patients who are unusually responsive to sympathomimetic amines. Albuterol may produce significant hypokalemia in some patients.In clinical trials, the most common adverse reactions reported for COMBIVENT RESPIMAT were upper respiratory tract infection, nasopharyngitis, cough, bronchitis, headache, and dyspnea.COMBIVENT RESPIMAT may interact additively with concomitantly used anticholinergic medications. Avoid co-administration with other anticholinergic-containing drugs.Caution is advised in co-administration of other beta-adrenergic agents, beta-receptor blocking agents, and non-potassium sparing diuretics. Extreme caution is advised with monoamine oxidase inhibitors or tricyclic antidepressants.This program is sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
Improvement in lung function
Dual bronchodilation of COMBIVENT RESPIMAT is proven clinically effective1
Study conducted with RESPIMAT and CFC-propelled inhalers
Percent improvement from baseline in lung function (day 85)1,2
§FEV1=forced expiratory volume in 1 second.
**CFC=chlorofluorocarbon.
COMBIVENT RESPIMAT was clinically comparable to COMBIVENT CFC across 6 hours and was superior to ipratropium RESPIMAT in the first 4 hours and noninferior in the last 2.1
Results from a randomized, double-blind, double-dummy, parallel-group, 12-week trial of 1460 adult patients conducted to demonstrate the efficacy and safety of COMBIVENT RESPIMAT (20/100 mcg) in COPD. Patients were randomized to one of the following active treatments: COMBIVENT RESPIMAT (20/100 mcg) (n=486), CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg) (n=491), and ipratropium bromide delivered by the RESPIMAT inhaler (20 mcg) (n=483) administered 4 times a day.1
The 3 primary efficacy comparisons were
- noninferiority of COMBIVENT RESPIMAT to CFC-propelled COMBIVENT Inhalation Aerosol for the FEV1 AUC0-6h on Test Day 85;
- superiority of COMBIVENT RESPIMAT to ipratropium RESPIMAT for the FEV1 AUC0-4h on Test Day 85, to demonstrate the contribution of albuterol in the combination product; and
- noninferiority of COMBIVENT RESPIMAT in comparison to ipratropium RESPIMAT for FEV1 AUC4-6h on Test Day 85, to demonstrate the contribution of ipratropium in the combination product.1
Safety
Adverse reactions in ≥2% of patients in the COMBIVENT RESPIMAT group in a 12-week COPD clinical trial1
| Body System (Event) | 12-Week Ipratropium-Controlled Trial | ||
| COMBIVENT RESPIMAT (20/100 mcg) [n=486] | Ipratropium bromide plus albuterol in a CFC¶ inhaler (36/206 mcg) [n=491] | Ipratropium bromide in the RESPIMAT Inhaler (20 mcg) [n=483] | |
| Patients with any adverse reaction | 46 | 52 | 45 |
| Respiratory, thoracic, and mediastinal disorders | |||
| Cough | 3 | 2 | 2 |
| Dyspnea | 2 | 2 | 3 |
| Nervous system disorders | |||
| Headache | 3 | 2 | 3 |
| Infections and infestations | |||
| Bronchitis | 3 | 3 | 1 |
| Nasopharyngitis | 4 | 3 | 4 |
| Upper respiratory infection | 3 | 4 | 3 |
12-Week Ipratropium-Controlled Trial
Body System (Event)
COMBIVENT RESPIMAT (20/100 mcg) [n=486]
46
Ipratropium bromide plus albuterol in a CFC** inhaler (36/206 mcg) [n=491]
52
Ipratropium bromide in the RESPIMAT inhaler (20 mcg) [n=483]
45
Respiratory, thoracic, and mediastinal disorders
COMBIVENT RESPIMAT (20/100 mcg) [n=486]
3
Ipratropium bromide plus albuterol in a CFC** inhaler (36/206 mcg) [n=491]
2
Ipratropium bromide in the RESPIMAT inhaler (20 mcg) [n=483]
2
COMBIVENT RESPIMAT (20/100 mcg) [n=486]
2
Ipratropium bromide plus albuterol in a CFC** inhaler (36/206 mcg) [n=491]
2
Ipratropium bromide in the RESPIMAT inhaler (20 mcg) [n=483]
3
Nervous system disorders
COMBIVENT RESPIMAT (20/100 mcg) [n=486]
3
Ipratropium bromide plus albuterol in a CFC** inhaler (36/206 mcg) [n=491]
2
Ipratropium bromide in the RESPIMAT inhaler (20 mcg) [n=483]
3
Infections and infestations
COMBIVENT RESPIMAT (20/100 mcg) [n=486]
3
Ipratropium bromide plus albuterol in a CFC** inhaler (36/206 mcg) [n=491]
3
Ipratropium bromide in the RESPIMAT inhaler (20 mcg) [n=483]
1
COMBIVENT RESPIMAT (20/100 mcg) [n=486]
4
Ipratropium bromide plus albuterol in a CFC** inhaler (36/206 mcg) [n=491]
3
Ipratropium bromide in the RESPIMAT inhaler (20 mcg) [n=483]
4
COMBIVENT RESPIMAT (20/100 mcg) [n=486]
3
Ipratropium bromide plus albuterol in a CFC** inhaler (36/206 mcg) [n=491]
4
Ipratropium bromide in the RESPIMAT inhaler (20 mcg) [n=483]
3
Adverse reactions that occurred in <2% in the COMBIVENT RESPIMAT (20/100 mcg) group observed in this 12-week trial include the following: vascular disorders: hypertension; nervous system disorders: dizziness and tremor; musculoskeletal and connective tissue disorders: muscle spasms and myalgia; gastrointestinal disorders: diarrhea, nausea, dry mouth, constipation, and vomiting; general disorders and administration-site conditions: asthenia, influenza-like illness, and chest discomfort; eye disorders: eye pain; metabolism and nutritional disorders: hypokalemia; cardiac disorders: palpitations and tachycardia; skin and subcutaneous tissue disorders: pruritus and rash; respiratory, thoracic, and mediastinal disorders: pharyngolaryngeal pain and wheezing.1
¶CFC=chlorofluorocarbon.
Designed to Ease Delivery
The RESPIMAT inhaler delivers nebulized medicine with ease into damaged lungs.3
References
-
COMBIVENT RESPIMAT Prescribing Information. Ridgefield CT; Boehringer Ingelheim Pharmaceuticals, Inc.; 2021.
-
Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
-
Wachtel H, Kattenbeck S, Dunne S, Disse B. The RESPIMAT® development story: patient-centric innovation. Pulm Ther. 2017;3(1):1-12.
COMBIVENT RESPIMAT is indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.
COMBIVENT RESPIMAT is contraindicated in patients hypersensitive to any of the ingredients of the drug product or to atropine or its derivatives.
COMBIVENT RESPIMAT can produce paradoxical bronchospasm that can be life-threatening. If it occurs, therapy with COMBIVENT RESPIMAT should be discontinued immediately and alternative therapy instituted.
The albuterol sulfate contained in COMBIVENT RESPIMAT can produce a clinically significant cardiovascular effect in some patients. If cardiovascular symptoms occur, COMBIVENT RESPIMAT may need to be discontinued.
COMBIVENT RESPIMAT should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
COMBIVENT RESPIMAT contains ipratropium bromide and may increase intraocular pressure which may result in precipitation or worsening of narrow-angle glaucoma. Use with caution in patients with narrow-angle glaucoma.
Patients should avoid spraying the aerosol into their eyes as this may cause acute eye pain or discomfort, temporary blurring of vision, mydriasis, visual halos, or colored images in association with red eyes from conjunctival or corneal congestion. Advise patients to consult their physician immediately if any of these symptoms develop while using COMBIVENT RESPIMAT.
Ipratropium bromide also may cause urinary retention.
Caution is advised when giving COMBIVENT RESPIMAT to patients with prostatic hyperplasia, or bladder-neck obstruction.
Since dizziness and blurred vision may occur with the use of COMBIVENT RESPIMAT, caution patients about engaging in activities such as driving a vehicle or operating appliances or machinery.
Do not exceed recommended dose. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma.
Hypersensitivity reactions including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema may occur. If such a reaction occurs, therapy with COMBIVENT RESPIMAT should be stopped at once and alternative treatment should be considered.
COMBIVENT RESPIMAT contains albuterol and should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus, and in patients who are unusually responsive to sympathomimetic amines. Albuterol may produce significant hypokalemia in some patients.
In clinical trials, the most common adverse reactions reported for COMBIVENT RESPIMAT were upper respiratory tract infection, nasopharyngitis, cough, bronchitis, headache, and dyspnea.
COMBIVENT RESPIMAT may interact additively with concomitantly used anticholinergic medications. Avoid co-administration with other anticholinergic-containing drugs.
Caution is advised in co-administration of other beta-adrenergic agents, beta-receptor blocking agents, and non-potassium sparing diuretics. Extreme caution is advised with monoamine oxidase inhibitors or tricyclic antidepressants.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
CL-CBR-100026 9.6.2022